Stocks Consumer discretionary OPRX
NASDAQ · Consumer discretionaryOptimizeRx Corp (OPRX)
OptimizeRx Corp brought in $98.7M of revenue over the twelve months to June 30, 2026, down 5.8% from a year earlier. Net income was $4.6M, a net margin of 4.7%. Operating cash flow minus capital spending left $18.7M of free cash flow in fiscal 2025. At June 30, 2026 it held $24.1M in cash against $19.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about OptimizeRx Corp
- Net worth
- OptimizeRx Corp has a market value (market cap) of $176.1M at the latest share price, and shareholders' equity of $131.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $109.4M (+18.8% year on year), with net income of $5.1M. Over the 12 months to June 30, 2026: revenue $98.7M, net income $4.6M.
- Cash flow
- In fiscal 2025 operations brought in $18.7M of cash; after $58K of capital spending, free cash flow was $18.7M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- OptimizeRx Corp's next report was expected around November 5, 2026 and is not on file with the SEC yet.
What OptimizeRx Corp does
OptimizeRx Corp is registered with the SEC under industry code SIC 7389 (Services-Business Services, NEC). Its shares trade on NASDAQ under the ticker OPRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $109.4M | $5.1M | $0.27 | $18.7M |
| 2024 | $92.1M | -$20.1M | -$1.10 | $4.8M |
| 2023 | $71.5M | -$17.6M | -$1.03 | -$7.3M |
| 2022 | $62.5M | -$11.4M | -$0.64 | $10.6M |
| 2021 | $61.3M | $378.1K | $0.02 | $625.7K |
| 2020 | $43.3M | -$2.2M | -$0.15 | -$6.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where OPRX ranks in Consumer discretionary
Latest SEC filings
What OptimizeRx Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 21, 2026Passive stake changed SCHEDULE 13G/A
- August 20, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 30% to $20.5M versus the same quarter last year; diluted EPS -$0.04 versus $0.08.
- August 12, 2026
- July 29, 2026Passive stake changed SCHEDULE 13G/A
- July 22, 2026Passive stake (5% or more) SCHEDULE 13G
- June 12, 2026
- June 5, 2026
- June 1, 2026Additional proxy material DEFA14A
What is OPRX worth? A DCF from its reported cash flow
Insider trades
What the people running OptimizeRx Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 11 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | D'Silva Andrew J.Chief Business Officer | Shares withheld for tax | 414 | $3.5K |
| September 1, 2026 | D'Silva Andrew J.Chief Business Officer | Shares withheld for tax | 1,432 | $11.3K |
| August 21, 2026 | Stelmakh EdwardChief Finance & Strat Officer | Shares withheld for tax | 1,381 | $10.6K |
| August 21, 2026 | D'Silva Andrew J.Chief Business Officer | Shares withheld for tax | 1,243 | $9.6K |
| August 21, 2026 | Odence-Ford MarionChief Legal & Admin Officer | Shares withheld for tax | 1,529 | $11.8K |
| August 21, 2026 | Silvestro Stephen LChief Executive Officer | Shares withheld for tax | 1,737 | $13.4K |
| August 21, 2026 | Merrell Brendan W.CHIEF OPERATING OFFICER | Shares withheld for tax | 1,020 | $7.9K |
| August 20, 2026 | Odence-Ford MarionChief Legal & Admin Officer | Received as pay | 57,600 | - |
Who owns OPRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Whetstone Capital Advisors, LLC13D, may seek influence with 1 related filers | 8.2% | April 21, 2025 |
| Kennedy Capital Management LLC13G, passive | 6.7% | August 14, 2026 |
| Royce & Associates LP13G, passive | 5.81% | July 22, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 113 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Whetstone Capital Advisors, LLC | 1,508,303 | 0 |
| Royce & Associates LP | 1,089,398 | +201,368 |
| Vanguard Capital Management LLC | 699,604 | +14,155 |
| Kennedy Capital Management LLC | 644,150 | -12,108 |
| Rice Hall James & Associates, LLC | 633,842 | +31,921 |
| Blair William & Co | 607,925 | -7,067 |
| Aqr Capital Management LLC | 583,956 | +369,002 |
| Dimensional Fund Advisors LP | 477,687 | -85,883 |
| BlackRock, Inc. | 445,382 | -718,119 |
| Parkman Healthcare Partners LLC | 350,347 | -379,022 |
| AWM Investment Company, Inc. | 240,421 | +10,000 |
| Geode Capital Management, LLC | 207,345 | -184,784 |
| Vanguard Portfolio Management LLC | 169,538 | -161,499 |
| Renaissance Technologies LLC | 167,700 | -49,156 |
| Marshall Wace, Llp | 162,186 | +130,900 |
| P.A.W. Capital Corp | 160,000 | +70,000 |
| Citadel Advisors LLC | 157,992 | new |
| Morgan Stanley | 156,314 | +79,946 |
| Mink Brook Asset Management LLC | 141,235 | new |
| D. E. Shaw & Co., Inc. | 138,084 | -4,839 |
Insiders
13 insiders reported holding 1,456,016 shares in total, about $13.6M at the last price.
| Holder | Shares |
|---|---|
| Lang James PaulDirector | 433,837 |
| Silvestro Stephen LChief Executive Officer | 183,551 |
| Stelmakh EdwardChief Finance & Strat Officer | 121,791 |
| Vos Ellen O'ConnorDirector | 107,159 |
| D'Silva Andrew J.Chief Business Officer | 99,246 |
| Wasson Gregory DDirector | 91,700 |
| Odence-Ford MarionChief Legal & Admin Officer | 90,407 |
| Spangler Patrick DDirector | 78,732 |
| Greco TheresaChief Commercial Officer | 71,075 |
| Besch DougChief Product & Tech Officer | 66,876 |
Questions about OPRX
What does OptimizeRx Corp do?
OptimizeRx Corp is a company in the Consumer discretionary sector, listed on NASDAQ as OPRX. Its shares trade on NASDAQ under the ticker OPRX.
What is OptimizeRx Corp's net worth?
OptimizeRx Corp has a market value (market cap) of $176.1M at the latest share price, and shareholders' equity of $131.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is OptimizeRx Corp profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $4.6M on revenue of $98.7M, a net margin of 4.7%.
How much revenue does OptimizeRx Corp make?
Over the twelve months to June 30, 2026 OptimizeRx Corp reported revenue of $98.7M. That is 5.8% less than a year earlier.
When did OptimizeRx Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from October 21, 2026.
When is OptimizeRx Corp's next earnings report?
OptimizeRx Corp's next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare OPRX with
Follow OPRX
Get an email when OptimizeRx Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values OptimizeRx Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.